PMID- 30352660
OWN - NLM
STAT- MEDLINE
DCOM- 20190923
LR  - 20190923
IS  - 1482-1826 (Electronic)
IS  - 1482-1826 (Linking)
VI  - 21
IP  - 1
DP  - 2018
TI  - Rh-endostatin Concomitant with Chemotherapy Versus Single Agent Chemotherapy for 
      Treating Soft Tissue and Bone Sarcomas: A Systematic Review and Meta-Analysis.
PG  - 386-397
LID - 10.18433/jpps30034 [doi]
AB  - Endostar (recombinant human endostatin (rh-endostatin)), a 20-kDa proteolytic 
      fragment of collagen XVIII, was approved for the treatment of non-small cell lung 
      cancer (NSCLC). Recently, several studies have evaluated the efficacy of 
      rh-endostatin combined with chemotherapy in the treatment of bone and soft tissue 
      sarcomas. Here, we conducted a systematic review and meta-analysis to assess 
      available evidence. Methods: Pubmed, Embase, Web of Sciences, the Cochrane 
      Library and two Chinese literature databases (CNKI, WanFang) were systematically 
      searched till May 20, 2018. Randomized controlled trials (RCTs) and cohort 
      studies which compared the outcomes of rh-endostatin combined with chemotherapy 
      versus chemotherapy alone for treating bone sarcomas or soft tissue sarcomas were 
      included. The primary outcome was overall survival rate (OSR). Secondary outcomes 
      included objectiveremissionrate(ORR), clinical benefit rate (CBR), disease 
      control rate (DCR), distant metastasis rate (DMR) and adverse effects (AEs). The 
      methodological quality of the included studies was evaluated. Data analysis was 
      performed by Revman 5.3 software. Results: 9 studies comprising 839 patients were 
      included. The pooled results indicated that, compared with chemotherapeutic 
      agents alone, rh-endostatin combined group had a significant benefit in 1-year 
      and 2-year OSR. However, there were no difference between 5-year OSR. OR, CBR and 
      DMR were higher in rh-endostatin combined group. No significant difference was 
      observed in the incidence of AEs. Conclusions: Rh-endostatin combined 
      chemotherapeutic agents significantly improved clinical efficacy compared with 
      chemotherapeutic agents alone in treating bone and soft tissue sarcomas. 
      Moreover, combination of rh-endostatin with chemotherapy didn't increase the 
      incidence of AEs. But more high quality RCTs with  large  sample  size  should  
      be  done  in  the  future  to confirm the conclusion.
FAU - Ma, Zhuo
AU  - Ma Z
AD  - Pharmacy Department of Beijing Chao-Yang Hospital, Capital Medical University, 
      Beijing 100020, P.R. China.
FAU - Guo, Lifang
AU  - Guo L
FAU - Cui, Xiangli
AU  - Cui X
FAU - Liu, He
AU  - Liu H
FAU - Liu, Lihong
AU  - Liu L
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - Switzerland
TA  - J Pharm Pharm Sci
JT  - Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian 
      Society for Pharmaceutical Sciences, Societe canadienne des sciences 
      pharmaceutiques
JID - 9807281
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Endostatins)
RN  - 0 (Recombinant Proteins)
RN  - GVG18ZDN65 (endostar protein)
SB  - IM
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Bone Neoplasms/*drug therapy/metabolism
MH  - Endostatins/*metabolism
MH  - Humans
MH  - Recombinant Proteins/*metabolism
MH  - Sarcoma/*drug therapy/metabolism
EDAT- 2018/10/26 06:00
MHDA- 2019/09/24 06:00
CRDT- 2018/10/25 06:00
PHST- 2018/10/25 06:00 [entrez]
PHST- 2018/10/26 06:00 [pubmed]
PHST- 2019/09/24 06:00 [medline]
AID - 10.18433/jpps30034 [doi]
PST - ppublish
SO  - J Pharm Pharm Sci. 2018;21(1):386-397. doi: 10.18433/jpps30034.